NVIDIA Corporation ignites the next battlefield: Joining forces with Johnson & Johnson (JNJ.US) and Eli Lilly (LLY.US), the trillion-dollar pharmaceutical industry welcomes the revolution of "AI surgery" and "pharmaceutical factories".

The CEO of NVIDIA Corporation (NVDA.US) stated on Tuesday that Johnson & Johnson (JNJ.US) and Eli Lilly and Company (LLY.US) are leveraging NVIDIA Corporation's technology to optimize existing products or support the development of new therapies. At the NVIDIA Corporation GTC conference held in Washington, Jensen Huang pointed out that Johnson & Johnson is using NVIDIA Corporation products to train part of the Siasun Robot&Automation for surgeries, and simulating surgical procedures through "digital twinning" technology. He said, "These Johnson & Johnson Siasun Robot&Automation surgeries will even be able to perform non-invasive procedures, with precision reaching unprecedented levels globally." Huang also mentioned a new collaboration between NVIDIA Corporation and Eli Lilly - they will jointly build a supercomputer. This computer will serve as an "AI factory," used for drug discovery as well as improving drug manufacturing processes. Thomas Fuchs, Senior Vice President and Chief AI Officer at Eli Lilly, stated in a release, "By embedding intelligence at every layer of our workflow, we're unlocking the door to a new enterprise model: one that continuously learns, adapts, and self-improves through every data point. It's not just about speed, it's about deeply exploring biological truths, enhancing our understanding of diseases, and translating these insights into meaningful medical advances for humanity..." This supercomputer will be the first based on Blackwell architecture, equipped with NVIDIA Corporation's DGX B300 system in a DGX SuperPOD, with power from over 1000 B300 graphic processing units (GPUs).